Navigation Links
IDEXX Laboratories Announces Fourth Quarter Results
Date:1/25/2008

per share:

Basic $0.42 $0.39 $1.53 $ 1.49

Earnings per share:

Diluted $0.40 $0.38 $1.46 $ 1.42

Shares outstanding:

Basic 61,186 62,523 61,560 62,866

Shares outstanding:

Diluted 64,156 65,472 64,455 65,907

Historical share and per share data has been retroactively restated to reflect the additional shares of common stock that were distributed on November 26, 2007 as a result of the two-for-one split of our outstanding common stock.

IDEXX Laboratories, Inc. and Subsidiaries

Key Operating Information (Unaudited)

Three Months Ended Twelve Months Ended

December 31, December 31, December 31, December 31,

2007 2006 2007 2006

Key Operating

Ratios (as a

percentage of

revenue):

Gross profit 49.9% 50.1% 50.2% 51.4%

Sales, marketing,

general and

administrative expense 28.1% 27.5% 28.1% 26.8%

Research and development

expense 6.8% 7.3% 7.3% 7.3%

Income from operations 15.0% 15.3% 14.8% 17.3%

International Revenue:

International revenue

(in thousands) $106,251 $70,590 $370,422 $260,945

International revenue as

percentage of total

revenue 43.4% 36.7% 40.2% 35.3%

IDEXX Laboratories, Inc. and Subsidiaries

Non-GAAP Financial Measures

Amounts in thousands except per share data (Unaudited)


'/>"/>

SOURCE IDEXX Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. IDEXX Laboratories to Release 2007 Fourth Quarter and Full-Year Financial Results
2. IDEXX Laboratories to Present at JPMorgan Healthcare Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
5. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Lawsuits Against Several Companies for Patent Infringement
6. RxElite Announces Acquisition of Assets of FineTech Laboratories
7. Parkway Clinical Laboratories Expands Management Team to Support a National Growth Strategy Centered on Oral Fluid Drug Screening
8. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Third Quarter Earnings
9. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
10. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
11. Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... , ... Transfinder, a software company based in Schenectady, N.Y., achieved record revenue ... for the first six months ended June 30, 2015 compared with the same period ... year’s record-revenue mark of $10.4 million. , “We know what our customers need and ...
(Date:7/31/2015)... ... 2015 , ... The Mount Sinai Health System will work with Columbia Care ... related, experimental treatments. The collaboration moves into the next phase with the recent decision ... five state licenses to produce and dispense medical marijuana. , Mount Sinai and ...
(Date:7/31/2015)... Falls Church, VA (PRWEB) , ... July 31, ... ... the Way, Oct. 20-21, 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having ... But it doesn’t have to. , Instead of risking containment — or even ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Patients with higher ... to a study published today in Nature Communications and led by researchers from the ... suggests that variations in the gene RTN1 led to greater production of the related ...
(Date:7/31/2015)... ... ... Down is a reputable source of authentic USA vs. Australia tickets at Ford ... National Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's World ... team was awarded the Golden Ball as the best player of the 2015 Women's World ...
Breaking Medicine News(10 mins):Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... coverage and access to health care , , FRIDAY, Jan. ... insurance and no regular source of health care are the ... University of Michigan C.S. Mott Children,s Hospital report. , The ... safeguard the health of vulnerable children, said the researchers, who ...
... Global Telemedicine Inc., supplies medical peripherals to the successful installations of ... advancing telemedicine program , ... N. Chelmsford, MA (PRWEB) ... Telemedicine has worked closely with Texas Tech University Health ...
... Jan. 30 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical, Co., Inc. (NYSE ... Chinese medicine ("TCM") based in Chengdu, China,today announced ... of shares,under its previously announced stock repurchase program. ... reducing the number of outstanding shares of its,common ...
... BOSTON, Jan. 30 Neurosilicon,s novel Photoconductive Stimulation Device ... Hung and Colicos titled, Astrocytic Ca2+ Waves Guide CNS ... article appearing in the November 2008 issue of The ... role of neuronal activity in mediating axonal guidance. It ...
... IDEXX Laboratories, Inc. (Nasdaq: IDXX ), ... 2008 were $243.3 million compared to $245.0 million for ... is reported growth adjusted to eliminate the effect of ... businesses acquired, divested or discontinued since October 1, 2007, ...
... ("QLT") (NASDAQ: QLTI ; TSX: QLT) announced the ... "Offer"), which expired at 5:00 p.m. (Eastern time) on January ... 20,000,000 of its common shares (the "Shares") at a price ... million. The purchased Shares represent approximately 26.8% of the Shares ...
Cached Medicine News:Health News:Medical Needs of 6.2 Million U.S. Kids Go Unmet 2Health News:Texas Tech University Health Sciences Center and AMD Global Telemedicine Inc. Expand Telemedicine Program Throughout Texas 2Health News:Texas Tech University Health Sciences Center and AMD Global Telemedicine Inc. Expand Telemedicine Program Throughout Texas 3Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 2Health News:Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program 3Health News:Novel Photoconductive Cellular Depolarization Technology Reveals Insight Into Neuronal Growth, Guidance, and Regeneration 2Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 2Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 3Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 4Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 5Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 6Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 7Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 8Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 9Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 10Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 11Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 12Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 13Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 14Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 15Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 16Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 17Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 18Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 19Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 20Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 21Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 22Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 23Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 24Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 25Health News:IDEXX Laboratories Announces Fourth Quarter and Full Year Results 26Health News:QLT announces final results of tender offer 2
(Date:7/30/2015)... 30, 2015  Today we bring you a special edition of #MedicareMonday on Medicare,s ... about some of our Medicare resources and continue highlighting the success of the prescription ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)...  Amgen (NASDAQ: AMGN ) today announced ... Key results include: , Total revenues increased ... to $5,370 million, with 6 percent product sales ... Prolia ® (denosumab), Sensipar ® (cinacalcet), ... (denosumab). Unfavorable changes in foreign exchange rates impacted ...
(Date:7/30/2015)... CHENGDU, China , July 30, 2015 ... "Company"), a pharmaceutical company that specializes in the patented ... active pharmaceutical ingredients (API), provided updates regarding the notice ... MKT LLC (the "Exchange") indicating that the Company was ... set forth in Sections 134 and 1101 of the ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... poultry ... processing plants., SHREVEPORT, La., Nov. ... poultry processing, was identified,in an October 2007 Watt Poultry USA article ... in large-scale processing plants, University of,Georgia Associate Professor of Poultry Science ...
... American Heart Association Scientific Sessions 2007 ... ... Nov. 6 ARCA Discovery, a privately held,biopharmaceutical company, announced today ... bucindolol, a,next-generation beta-blocker and vasodilator for heart failure, atrial,fibrillation, and arrhythmia, ...
Cached Medicine Technology:FreshFx Recognized for use in the Scalder as a Solution to the 'Yield/Pathogen Reduction Dilemma' 2ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia 2ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia 3ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia 4ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: